Chronic constipation affects millions worldwide, yet the fundamental mechanisms controlling the powerful colonic contractions that enable normal defecation have remained poorly understood. This knowledge gap has limited therapeutic options for the estimated 16% of adults experiencing chronic bowel movement difficulties.
Researchers using the Suncus murinus model have identified adenosine triphosphate (ATP) as a previously unknown master regulator of giant migrating contractions—the forceful waves that propel waste through the colon. When ATP was administered intravenously at doses of 5-200 mg/kg, it triggered strong contractions nearly identical to naturally occurring ones. The effect operated through P2X7 receptors, as specific antagonists blocked the response while P2X7 agonists replicated it. Crucially, ATP required cholinergic nervous system activation, as atropine completely prevented the contractions.
This discovery fills a critical mechanistic void in understanding colonic motility disorders. Current treatments for constipation largely rely on bulk-forming agents or osmotic laxatives rather than targeting the underlying neuromotor dysfunction. The ATP-P2X7-cholinergic pathway represents the first identified endogenous signaling cascade specifically controlling these essential propulsive contractions. However, several limitations temper immediate clinical translation. The research used a single animal model, and in vitro tissue studies failed to reproduce the effects, suggesting complex in vivo neural integration is required. Additionally, the therapeutic window between effective ATP dosing and potential systemic toxicity remains undefined. Nevertheless, this pathway opens promising avenues for developing targeted therapies that restore normal colonic propulsion rather than simply adding bulk or water to stool.